elevated lipase semaglutide Comparative safety and side effects of and tirzepatide: Implications for clinical decision-making in obesity management Mechanisms of Non-alcoholic Fatty Liver

AWARD-7 enrolled adult patients with T2D (A1c, 7.5%10.5%) and CKD stages 34 who were being treated with ACEi or ARBs and found that dulaglutide (0.75 or 1.5 mg subcutaneous once weekly) achieved similar glycemic control to insulin glargine but had significantly less eGFR decline (mean 0.7 vs 3.3 mL/min/1.73 m 2 , respectively

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

Manufacturer precautions reflect the absence of safety data rather than documented harm, meaning the true risk level remains unknown

Vomiting: 20-21%

This maintains safety and effectiveness without overwhelming your system

While highly effective for many, individual responses can vary, emphasizing the need for personalized treatment